DE60135390D1 - Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration - Google Patents
Verwendung von nefiracetam zur behandlung von postischemischer neurodegenerationInfo
- Publication number
- DE60135390D1 DE60135390D1 DE60135390T DE60135390T DE60135390D1 DE 60135390 D1 DE60135390 D1 DE 60135390D1 DE 60135390 T DE60135390 T DE 60135390T DE 60135390 T DE60135390 T DE 60135390T DE 60135390 D1 DE60135390 D1 DE 60135390D1
- Authority
- DE
- Germany
- Prior art keywords
- nefiracetam
- neurodegeneration
- treatment
- postic
- mixer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- NGHTXZCKLWZPGK-UHFFFAOYSA-N nefiracetam Chemical compound CC1=CC=CC(C)=C1NC(=O)CN1C(=O)CCC1 NGHTXZCKLWZPGK-UHFFFAOYSA-N 0.000 title abstract 3
- 229950004663 nefiracetam Drugs 0.000 title abstract 2
- 230000004770 neurodegeneration Effects 0.000 title abstract 2
- 208000006011 Stroke Diseases 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 238000011084 recovery Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP2001/007180 WO2003018005A1 (en) | 2001-08-22 | 2001-08-22 | use of nefiracetam for treating neurodegeneration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60135390D1 true DE60135390D1 (de) | 2008-09-25 |
Family
ID=11737657
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60135390T Expired - Lifetime DE60135390D1 (de) | 2001-08-22 | 2001-08-22 | Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20040192759A1 (enExample) |
| EP (1) | EP1420782B1 (enExample) |
| JP (1) | JP2005501108A (enExample) |
| AT (1) | ATE404192T1 (enExample) |
| CA (1) | CA2457982C (enExample) |
| DE (1) | DE60135390D1 (enExample) |
| ES (1) | ES2311537T3 (enExample) |
| WO (1) | WO2003018005A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060241144A1 (en) | 2005-04-20 | 2006-10-26 | Albert Cha | Method for treating apathy syndrome |
| RU2329804C2 (ru) * | 2006-03-28 | 2008-07-27 | Валентина Ивановна Ахапкина | Вещество, обладающее нейротропной - нейромодуляторной активностью |
| EP2346500B1 (en) * | 2008-10-16 | 2017-05-17 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| ES2664727T3 (es) * | 2009-10-22 | 2018-04-23 | University College Dublin National University Of Ireland, Dublin | Terapia causal de enfermedades o estados asociados con desmielinización del SNC o del SNP |
| EP2533645B1 (en) * | 2010-02-09 | 2016-07-27 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| CA2904767C (en) | 2013-03-15 | 2022-06-21 | Agenebio, Inc. | Methods and compositions for improving cognitive function |
| US10806717B2 (en) | 2013-03-15 | 2020-10-20 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| EA034167B8 (ru) | 2015-05-22 | 2021-04-27 | Эйджинбайо, Инк. | Фармацевтические композиции леветирацетама пролонгированного высвобождения |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4749700A (en) * | 1984-10-23 | 1988-06-07 | Nastech Pharmaceutical Co, Inc. | Novel methods of administering antihistamines, antinausea and antiemetic pharmaceutical agents and novel dosage forms containing same |
| SK279285B6 (sk) * | 1991-05-02 | 1998-09-09 | Daiichi Pharmaceutical Co. | Použitie n-(2,6-dimetylfenyl)-2-(2-oxo-1-pyrolidin |
| JP3388778B2 (ja) * | 1991-05-02 | 2003-03-24 | 第一製薬株式会社 | 脳血管性痴呆改善剤 |
| AU8131198A (en) * | 1997-07-15 | 1999-02-10 | Daiichi Pharmaceutical Co., Ltd. | Prophylactic or therapeutic agent for amnesia |
| JPH1180027A (ja) * | 1997-09-12 | 1999-03-23 | Dai Ichi Seiyaku Co Ltd | 向知性薬 |
| US6423739B1 (en) * | 2000-02-23 | 2002-07-23 | Daiichi Pharmaceutical Co., Ltd. | Method for aiding cerebral recovery following neurodegeneration |
-
2001
- 2001-08-22 AT AT01958395T patent/ATE404192T1/de not_active IP Right Cessation
- 2001-08-22 CA CA002457982A patent/CA2457982C/en not_active Expired - Fee Related
- 2001-08-22 ES ES01958395T patent/ES2311537T3/es not_active Expired - Lifetime
- 2001-08-22 JP JP2003522525A patent/JP2005501108A/ja active Pending
- 2001-08-22 DE DE60135390T patent/DE60135390D1/de not_active Expired - Lifetime
- 2001-08-22 WO PCT/JP2001/007180 patent/WO2003018005A1/en not_active Ceased
- 2001-08-22 EP EP01958395A patent/EP1420782B1/en not_active Expired - Lifetime
- 2001-08-22 US US10/487,320 patent/US20040192759A1/en not_active Abandoned
-
2007
- 2007-09-28 US US11/863,808 patent/US20080076820A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003018005A1 (en) | 2003-03-06 |
| EP1420782A1 (en) | 2004-05-26 |
| CA2457982A1 (en) | 2003-03-06 |
| ATE404192T1 (de) | 2008-08-15 |
| EP1420782B1 (en) | 2008-08-13 |
| ES2311537T3 (es) | 2009-02-16 |
| US20040192759A1 (en) | 2004-09-30 |
| CA2457982C (en) | 2009-11-03 |
| JP2005501108A (ja) | 2005-01-13 |
| US20080076820A1 (en) | 2008-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG106825A (en) | Substituted oxazolidinones and their use in the field of blood coagulation | |
| FR2843125B1 (fr) | Principes actifs stimulant les beta-defensives humaines de type 2 et/ou de type 3, et compositions cosmetiques ou pharmaceutiques comprenant de tels principes actifs | |
| ATE405564T1 (de) | 1h-imidazoä4,5-cüchinolinderivate zur behandlung von protein kinase-abhängigen krankheiten | |
| AP1818A (en) | Urea-compounds active as vanilloid receptor antagonists for the treatment of pain | |
| BR0311313A (pt) | Derivados de diaril uréia úteis para o tratamento de doenças dependentes de proteìna cinase | |
| BRPI0412526A (pt) | composto, uso de um composto, composição farmacêutica, formulação em aerossol farmacêutica, e, método para o tratamento de um paciente humano ou animal com uma condição anti-inflamatória e/ou alérgica | |
| BG106095A (bg) | Нови лекарствени състави на базата на антихолинергично активни съединения и бета-миметици | |
| GEP20053546B (en) | Crystalline Forms of 'R-(R*,R*)!-2-(4- Fluorophenyl)-Beta, Delta-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-'Phenylamino) Carbonyl!-1H-Pyrrole-1-Heptanoic Acid Calcium Salt (2:1) (Atorvastatin) | |
| CY1107850T1 (el) | Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους | |
| CY1112376T1 (el) | Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2 | |
| ATE332138T1 (de) | Flibanserin zur behandlung extrapyramidaler bewegungsstörungen | |
| ATE396967T1 (de) | (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten | |
| BR0314797A (pt) | Derivados da pirimidineamida e o uso dos mesmos | |
| ATE298324T1 (de) | Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel | |
| ATE260650T1 (de) | Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac | |
| ATE404192T1 (de) | Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration | |
| DE60220055D1 (de) | 4-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)harnstoff und dessen verwendung bei der behandlung von mit glycogensynthasekinase-3 (gsk3) assoziierten leiden | |
| DE60035429D1 (de) | Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen | |
| ATE157871T1 (de) | Arzneimittel zur therapeutischen und prophylaktischen behandlung von krankheiten, die durch hyperplasie der glatten muskelzellen bedingt sind | |
| BR9708297A (pt) | Compostos composição farmacéutica cosmposição e uso de uma composição cosmética | |
| HUP9802897A2 (hu) | Optikailag aktív piridil-4H-1,2,4-oxadiazin-származék, annak alkalmazása vaszkuláris betegségek kezelésére, valamint ilyen származékot hatóanyagként tartalmazó gyógyászati készítmény | |
| RU2001118854A (ru) | Оптически активное производное пиридил-4н-1,2,4-оксадиазина и его применение при лечении сосудистых заболеваний | |
| HUP9902135A2 (hu) | (+)-alfa-(2,3-Dimetoxi-fenil)-1-[2-(4-fluor-fenil)-etil]-4-piperidin-metanol alkalmazása depresszív és bipoláris rendellenességek kezelésére alkalmas gyógyszerkészítmény előállítására | |
| BR0104586A (pt) | Método para tratamento de neurodegeneração | |
| DE602004029993D1 (de) | Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |